Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...

The firm is using single-cell, multiomics analysis to probe tumor samples from very long-term cancer survivors for keys to defeat the disease.

Single-cell transcriptomics has revolutionized the study of cellular diversity and function by enabling gene expression analysis at single-cell resolution. The technique is crucial for understanding ...

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

What a brutal six months it’s been for 10x Genomics. The stock has dropped 52.1% and now trades at $10.59, rattling many ...

Cure51 and Assistance Publique – Hôpitaux de Paris have partnered to identify biomarkers for long-term survival in pancreatic cancer.

Parse’s chromatin accessibility technology leverages a novel approach with advantages over existing methods such as ATAC-seq ...

Why do women's brains fare better in aging than men's? A study found that the second, 'silent' X chromosome turns on in the ...

Parse Biosciences, the leader in accessible and scalable single cell sequencing, today affirmed their plans to proceed with development and future ...

Genomics , a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, 2025, in the ...

Genomics announced that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived ...